EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0RC6: Pharma Mar SA

01 Sep 2025
LAST:

84.15

CHANGE:
 2.85		OPEN:
81.10		HIGH:
86.60		ASK:
74.70		VOLUME:
2.2K
CHG(%):
3.51		PREV:
81.30		LOW:
80.35		BID:
71.10		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
01 Sep 2581.1086.6080.3584.152.2K
29 Aug 2582.8083.6081.0081.30582
28 Aug 2580.1083.1580.0082.55943
27 Aug 2579.2581.4079.2580.60759
26 Aug 2580.8081.4380.0581.431.2K
25 Aug 2581.1382.6579.1082.05423
22 Aug 2580.9082.6579.1082.46399
21 Aug 2579.6081.7079.6080.75125
20 Aug 2580.1580.5579.6580.55538
19 Aug 2584.8584.8580.3080.951.8K

COMPANY PROFILE

Name:Pharma Mar SA
About:Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca is a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company develops Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating choroidal neovascularization, such as macular degeneration and diabetic retinopathy; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Address:Avenida de los Reyes, 1, Madrid, Spain, 28770
Website:https://www.pharmamar.com
ISIN:ES0169501022
LEI:959800QWKZ45ZQC2AV58

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:0.15
DivYield:0.01
Div/Share:0.80
PtS:86.58
EBITDA:35.93M
Shares:221.28M
Market Cap:18.62B

TECHNICAL INDICATORS

MA5:82.01
MA10:81.68
MA20:81.10
MA50:80.95
MA100:80.61
MA200:82.38
STO9:59.50
STO14:59.50
RSI14:62.66
MTM14:1.75
ROC14:0.02
ATR:3.19
Week High:86.60
Week Low:79.10
Month High:86.60
Month Low:77.35
Year High:105.60
Year Low:38.99
Volatility:1.49

RECENT SPLITS

Date Ratio
22 Jul 20201-12

RECENT DIVIDENDS

Date Amount
25 Jun 2025$0.80
12 Jun 2024$0.65
07 Jun 2023$0.53
13 Jul 2022$0.53
28 Apr 2021$0.49
26 Jun 2020$0.39
09 Jul 2008$0.06
06 Jul 2007$0.06